Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 7/26/2017 11:58:25 AM - Followers: 164 - Board type: Free - Posts Today: 6


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS News: Current Report Filing (8-k) 07/25/2017 09:37:37 AM
OXIS News: Withdrawal of Registration Statement (rw) 07/24/2017 11:34:32 AM
OXIS News: Current Report Filing (8-k) 06/26/2017 08:01:21 AM
OXIS News: Information Statement - All Other (definitive) (def 14c) 05/12/2017 04:03:59 PM
OXIS News: Information Statements (revised) (prer14c) 05/05/2017 05:21:15 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#10701   yes, but ur premiums, wont be worth ur time! Fibanotch 07/26/17 11:58:24 AM
#10700   Right after the reverse split will be a simon wagstaff 07/26/17 11:35:54 AM
#10699   You should be fine, like others have said oxis007 07/26/17 11:25:19 AM
#10698   With a 1:300 split you'll end up with CashBowski 07/26/17 10:42:08 AM
#10697   I am confused. What milestones have been accomplished? simon wagstaff 07/26/17 08:56:08 AM
#10696   I have 111,880 shares at an average of oxisHOG 07/26/17 08:23:03 AM
#10695   Oxis agreed to pay 33 percent of its JayP-Diddy 07/25/17 04:51:18 PM
#10694   Wow, an additional 4.8 billion shares being added CashBowski 07/25/17 03:59:28 PM
#10693   Ok cool! I'm watching..... jimbosskow 07/25/17 01:10:21 PM
#10692   The new CEO is a she, not a mrcraigo 07/25/17 12:50:18 PM
#10691   NEWS: Oxis Releases Additional Details About Acquisition of zeekhoe 07/25/17 11:30:25 AM
#10690   Look at the last slide of their new oxis007 07/25/17 10:51:16 AM
#10689   Any none what the the weight of this oxisHOG 07/25/17 10:37:46 AM
#10688   I would like to see more of the jimbosskow 07/25/17 10:29:11 AM
#10687   Jim did you see it the newest email Bishop123 07/25/17 10:24:49 AM
#10686   I think they trying to work up the jimbosskow 07/24/17 09:37:17 PM
#10685   OXIS INTERNATIONAL, INC. jimbosskow 07/24/17 09:14:18 PM
#10684   Can you please post where it says the JayZee4 07/24/17 07:39:14 PM
#10683   If they would withdraw from the R/S I jimbosskow 07/24/17 03:35:36 PM
#10682   For me the best news would be to scoot27 07/24/17 03:25:02 PM
#10679   So if they cancelled selling more notes does Bishop123 07/24/17 02:28:57 PM
#10678   Thank u Bishop123 07/24/17 12:50:14 PM
#10677   The document S-1 from 8/24/16 was related to scoot27 07/24/17 12:42:50 PM
#10676   Okay can someone tell me what the email Bishop123 07/24/17 12:33:05 PM
#10675   Anybody know what this means new news no Bishop123 07/24/17 12:16:29 PM
#10674   1615EpCAM133 oxis007 07/23/17 10:24:06 PM
#10673   Great things to come after this merger. Even JayZee4 07/23/17 11:33:29 AM
#10672   If access can just forget about the reverse Bishop123 07/21/17 01:02:12 PM
#10671   Does anyone know when the new CMO will oxisHOG 07/21/17 08:20:50 AM
#10670   Liking the new website Harry17 07/20/17 09:32:40 AM
#10669   Lots of volume lately looking like a pop soon stern10 07/19/17 12:38:01 AM
#10668   Some interesting pieces from this link oxis007 07/18/17 07:14:28 PM
#10667   Lots of new players involved Bishop123 07/18/17 08:04:56 AM
#10666   I will be impressed only when it is scoot27 07/17/17 04:31:51 PM
#10665   Great day!! Hopefully .03 tomorrow!!! stern10 07/17/17 04:14:36 PM
#10664   Let's go Oxis .2+++ stern10 07/17/17 04:01:25 PM
#10663   Oxis to the moon baby! :) MrBond007 07/17/17 01:07:17 PM
#10662   First comes volume. Then comes price. drive 07/17/17 11:11:40 AM
#10661   Let's go!!!!! stern10 07/17/17 10:36:52 AM
#10660   Any idea on when reverse stock split will oxisHOG 07/17/17 08:28:01 AM
#10659   I think Cataldo might do a shareholder letter oxis007 07/16/17 11:21:22 PM
#10658   Hopefully this will have a good outcome for Gumby525 07/16/17 09:29:54 PM
#10657 Trial starts October oxis007 07/16/17 07:06:52 PM
#10653   I have not lost any money :) MrBond007 07/13/17 12:13:26 PM
#10652   Welcome to OXIS where most everyone is down. Gibba 07/13/17 10:03:01 AM
#10650   I bought in £18,232 GBP MrBond007 07/12/17 12:30:28 PM
#10649   Why do you keep switching currency in the oxis007 07/12/17 12:11:40 PM
#10648   I have spent £18,226 on my shares which MrBond007 07/12/17 10:58:45 AM
#10647   Correct you will have 5300 shares at $3.44 each. oxis007 07/12/17 10:04:37 AM
#10646   I have 530,000 shares MrBond007 07/12/17 09:30:16 AM